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Background
After years of development, oncolytic viruses are nearing
a breakthrough into clinical use. In order to facilitate
the implementation of this new form of immunotherapy,
all existing clinical experience must be utilized to opti-
mize treatment strategies, improve patient selection and
develop even more effective oncolytic therapeutics.
Here we report clinical factors that affected the prog-
nosis and predicted treatment efficacy in 290 patients trea-
ted with oncolytic adenoviruses. In these analyses, survival
and efficacy determined by radiological response criteria
were used as dependent variables in multi-parameter
regression models. In prognostic models measuring hazard
ratio (HR) for cancer mortality, tumor type and virus
arming were found to affect the prognosis of the patients
significantly. Gynecological tumors were notably linked to
better prognosis (HR 0.477, p=0,004). Patients treated with
viruses coding for GMCSF (HR 0.549, p=0.003) or
GMCSF-coding viruses and CD40L-coding viruses (HR
0.439, p=0.023) were more likely to survive longer. In the
predictive models the administration of the virus was dis-
covered to independently influence the efficacy of the
treatment. Patients who received most of the treatments
as intraperitoneal injections were more likely to achieve
disease control status (OR 3.878, p=0.016). In a small sub-
set of patients (n=13) who received all treatments intrave-
nously the probability of disease control was even higher
(OR 8.995, p=0.032).
Conclusions
These data indicate several options for further develop-
ment of oncolytic adenovirus therapy. Concentration on
sensitive diseases and choosing the right patient subsets
for treatment, as well as finding optimal administration
schemes, are key steps in improving the therapeutic
efficacy of adenoviruses. The results suggest that evalu-
ating the immunological status of the patients before
oncolytic virotherapy can offer important prognostic
information. In order to be translated to the field of per-
sonalized oncology, this concept requires still further
investigation.
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